Free Trial
NASDAQ:NTRB

Nutriband 5/30/2025 Earnings Report

Nutriband logo
$8.53 -0.28 (-3.18%)
Closing price 04:00 PM Eastern
Extended Trading
$8.54 +0.01 (+0.06%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nutriband EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.13
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Nutriband Revenue Results

Actual Revenue
$0.67 million
Expected Revenue
$0.71 million
Beat/Miss
Missed by -$40.00 thousand
YoY Revenue Growth
N/A

Nutriband Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nutriband's next earnings date is estimated for Tuesday, September 2, 2025, based on past reporting schedules.

Conference Call Resources

Nutriband Earnings Headlines

Altucher: Turn $900 into $108,000 in just 12 months?
Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.
See More Nutriband Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email.

About Nutriband

Nutriband (NASDAQ:NTRB) develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

View Nutriband Profile

More Earnings Resources from MarketBeat